Zynex Inc (NASDAQ:ZYXI), a developer of non-invasive medical devices, is laying the foundation for a return to growth following a pivotal second quarter marked by leadership changes, operational streamlining, and a key FDA submission for its next-generation pulse oximeter.
The company appointed industry veteran Steven Dyson as CEO in Q2, a move founder Thomas Sandgaard called “transformational” for the Colorado-based firm.
CVS Health Corp (NYSE:CVS) reported better-than-expected financial results for the second quarter, driven by robust growth across its retail pharmacy, insurance (Aetna), and health services segments.
Total revenue was up 8.4% at $98.9 billion, above Wall Street estimates of $94.7 billion.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF), the UK biotechnology company specialising in allergy immunotherapies, has published three new studies in the journal Allergy that strengthen the evidence for its investigational grass pollen allergy treatment, Grass MATA MPL.
The papers focus on the treatment's use in combating allergic rhinoconjunctivitis, a condition involving both nasal and eye symptoms triggered by grass pollen.
GSK PLC (LSE:GSK, NYSE:GSK) delivered a strong set of second-quarter results, beating expectations on sales, profits, and earnings per share, and raised its guidance to the top end of its previous range.
However, UBS analysts caution that much of this outperformance was driven by timing effects, such as early HIV medicine orders and stock builds, particularly in France for the Shingrix vaccine, which are likely to reverse later in the year.
NanoViricides (NYSE-A:NNVC) said on Wednesday that its antiviral candidate NV-387 could play a key role in addressing the growing number of measles cases globally, particularly in industrialized nations including the US, Canada, the UK, and the EU.
The company said NV-387 has shown safety and effectiveness in preclinical studies using humanized mouse models and has completed a Phase I clinical trial with no reported adverse events, supporting its potential as a measles treatment.
AstraZeneca PLC (LSE:AZN) shares have caught the attention of UBS, which reiterated its 'buy' rating and raised its price target to 14,200p, implying over 27% upside from the current level, after a solid set of second-quarter results.
The drugmaker beat the Swiss Bank's estimates on both sales and operating profit, helped by stronger-than-expected growth in US oncology and a rebound in its rare disease division.
Shares in Novo Nordisk (NYSE:NVO) are under the spotlight after a surprise profit warning, which, while denting the share price, failed to the wreak the damage some might have feared.
That said, the 3.6% fall in the stock piles on the pain for the Ozempic maker, which was formerly Europe's most valuable company.
GSK PLC (LSE:GSK, NYSE:GSK) said on Wednesday it expects to deliver results at the top end of its guidance for the year after reporting a robust second quarter, fuelled by strong sales in its Specialty Medicines and Vaccines businesses.
The pharmaceuticals giant posted sales of £8 billion for the three months to June, up 6% at constant exchange rates.
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) on Wednesday issued results for the June quarter highlighting the first patient dosing in its Phase 2a trial of PTX-100 for cutaneous T-cell lymphoma (CTCL), following the US FDA’s decision to grant the investigational cancer therapy Fast Track designation.
The designation provides access to expedited regulatory pathways in the US, recognising PTX-100’s potential to address an unmet need in relapsed or refractory mycosis fungoides, the most common CTCL subtype. Prescient closed the quarter with $6.9 million in cash and later raised a further $6.8 million via a Share Purchase Plan (SPP), which concluded in July.
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has executed a First Amended and Restated Master Services Agreement (A&R MSA) with Switchback Medical, LLC to support the development and manufacture of its structural heart devices.
The updated agreement, signed on July 28, 2025, outlines Switchback’s continued provision of engineering, testing, and manufacturing services under defined purchase orders and pricing structures. All activities are to be carried out in line with regulatory and quality management standards.
AstraZeneca PLC (LSE:AZN) saw £3.3 billion added to its market value after delivering a strong set of half-year results and confirming its guidance for 2025.
The group reported second-quarter revenue of $14.46 billion, up 12%, driven by double-digit gains in oncology and biopharmaceuticals. Core earnings per share for the quarter rose 10% to $2.17, with reported earnings per share climbing 27% to $1.58.
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares jumped 25% at the open on Tuesday after the US Food and Drug Administration recommended the company lift a voluntary pause on shipments of its gene therapy ELEVIDYS for ambulatory Duchenne muscular dystrophy (DMD) patients.
The regulator’s move follows its determination that the death of an eight-year-old patient in Brazil, which had prompted a temporary halt, was unrelated to the therapy. The patient’s death on July 25, was attributed to complications from a severe flu infection and immunosuppression, according to media reports and company disclosures.
Merck & Co Inc (NYSE:MRK, ETR:6MK) shares moved lower in early trade as the pharmaceutical company reported second quarter earnings that fell short of estimates.
Revenue for the quarter came in at $15.8 billion, down 2% year-over-year and below consensus expectations of approximately $15.75 billion.
UnitedHealth Group Inc (NYSE:UNH, ETR:UNH) reported second-quarter earnings that fell short of Wall Street expectations and reinstated a full-year forecast well below consensus.
The company posted adjusted earnings of $4.08 per share for the quarter ended June 30, significantly below analysts' estimates of $4.45, and marking a 14% decline from a year earlier. Earnings from operations also fell 34% to $5.2 billion, while net margin narrowed by 120 basis points to 3.1%.
AstraZeneca PLC (LSE:AZN) has reiterated its full-year guidance for 2025, following a robust set of results for the second quarter and first half, and pointed to a series of significant late-stage trial successes across its research and development pipeline.
The pharmaceutical group reported total revenue of $14.46 billion for the second quarter, up 12% compared with the same period last year at actual exchange rates, driven by double-digit growth in oncology and biopharmaceuticals.
hVIVO PLC (AIM:HVO), the contract research group specialising in human challenge clinical trials, said it plans to appoint Shaun Chilton as its new chair.
He brings more than 30 years’ experience in leading and managing both private and listed companies.
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has raised A$6.8 million via a Share Purchase Plan (SPP) to accelerate Phase 2 clinical development of its lead cancer therapy candidate, PTX-100. In response to investor interest beyond the SPP cap, the company has entered a trading halt to launch a follow-on placement to sophisticated and professional investors at the same share price of A$0.04 — an 11.1% discount to the last traded price on July 28, 2025.
The funds will support PTX-100’s continued development toward regulatory approval.
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said on Friday that its platform company, Recognify Life Sciences, reported top-line results from a Phase 2b trial of inidascamine in cognitive impairment associated with schizophrenia (CIAS), which did not meet the primary endpoint but demonstrated consistent signs of cognitive and functional benefit and maintained a favorable safety profile.
The double-blind, placebo-controlled study enrolled 242 patients and tested two doses of inidascamine over a six-week treatment period.
Shares in GSK PLC (LSE:GSK, NYSE:GSK) rose in morning trading after the pharmaceutical group announced a $500 million collaboration with Hengrui Pharma to co-develop up to 12 experimental medicines, in a deal that could be worth as much as $12 billion.
The agreement includes global rights (excluding China and a few territories) to HRS-9821, a potential new treatment for chronic obstructive pulmonary disease (COPD).
Avacta Group PLC (AIM:AVCT) announced the sale of its subsidiary, Coris Bioconcept, to 3B BlackBio Dx Ltd, for £2.15 million in upfront cash plus up to £615,000 in potential earn-outs.
Completion is expected in August 2025, subject to closing conditions.
It was a quiet start to the week for shares in Smith & Nephew PLC (LSE:SN). But perhaps it is the calm before the storm for the medical devices giant, which faces a shareholder revolt.
Activist investor Cevian Capital has increased its stake to 8.5%, intensifying pressure on the FTSE 100 group ahead of half-year results due on August 5.
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay $500 million in upfront fees to Chinese drugmaker Hengrui Pharma as part of a wide-ranging collaboration to develop up to 12 experimental medicines in a deal worth up to a potential $12 billion.
It is the latest move by the British giant to bolster its pipeline beyond 2031.